CL2010000823A1 - Anticuerpo anti-cd-20 con actividad apoptotica; polinucleotido, vector y celula huesped que expresa el anticuerpo; composicion farmaceutica que lo comprende; usos en la preparacion de un medicamento para tratar cancer o una enfermedad autoinmune; metodo para producir dicho anticuerpo (div. sol. n°2246-06). - Google Patents

Anticuerpo anti-cd-20 con actividad apoptotica; polinucleotido, vector y celula huesped que expresa el anticuerpo; composicion farmaceutica que lo comprende; usos en la preparacion de un medicamento para tratar cancer o una enfermedad autoinmune; metodo para producir dicho anticuerpo (div. sol. n°2246-06).

Info

Publication number
CL2010000823A1
CL2010000823A1 CL2010000823A CL2010000823A CL2010000823A1 CL 2010000823 A1 CL2010000823 A1 CL 2010000823A1 CL 2010000823 A CL2010000823 A CL 2010000823A CL 2010000823 A CL2010000823 A CL 2010000823A CL 2010000823 A1 CL2010000823 A1 CL 2010000823A1
Authority
CL
Chile
Prior art keywords
antibody
vector
pharmaceutical composition
producing
div
Prior art date
Application number
CL2010000823A
Other languages
English (en)
Spanish (es)
Inventor
Ekkehard Mössner
Pablo Umaña
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37865318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010000823(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CL2010000823A1 publication Critical patent/CL2010000823A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
CL2010000823A 2005-08-26 2010-07-30 Anticuerpo anti-cd-20 con actividad apoptotica; polinucleotido, vector y celula huesped que expresa el anticuerpo; composicion farmaceutica que lo comprende; usos en la preparacion de un medicamento para tratar cancer o una enfermedad autoinmune; metodo para producir dicho anticuerpo (div. sol. n°2246-06). CL2010000823A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71145405P 2005-08-26 2005-08-26

Publications (1)

Publication Number Publication Date
CL2010000823A1 true CL2010000823A1 (es) 2011-01-07

Family

ID=37865318

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2010000823A CL2010000823A1 (es) 2005-08-26 2010-07-30 Anticuerpo anti-cd-20 con actividad apoptotica; polinucleotido, vector y celula huesped que expresa el anticuerpo; composicion farmaceutica que lo comprende; usos en la preparacion de un medicamento para tratar cancer o una enfermedad autoinmune; metodo para producir dicho anticuerpo (div. sol. n°2246-06).
CL2010000822A CL2010000822A1 (es) 2005-08-26 2010-07-30 Anticuerpo humanizado anti-cd20 el cual induce mayores niveles de apoptosis cuando esta formando un complejo con cd20, en comparacion al anticuerpo parental; composición farmaceutica; uso para tratar desordenes que responden a la eliminación de células b; polinucleotido codificante; vector, célula huésped; método de producción. (divisional solicitud n° 2246-06).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2010000822A CL2010000822A1 (es) 2005-08-26 2010-07-30 Anticuerpo humanizado anti-cd20 el cual induce mayores niveles de apoptosis cuando esta formando un complejo con cd20, en comparacion al anticuerpo parental; composición farmaceutica; uso para tratar desordenes que responden a la eliminación de células b; polinucleotido codificante; vector, célula huésped; método de producción. (divisional solicitud n° 2246-06).

Country Status (18)

Country Link
US (2) US20070071745A1 (OSRAM)
EP (3) EP2395023B1 (OSRAM)
JP (3) JP5373396B2 (OSRAM)
KR (2) KR101379568B1 (OSRAM)
CN (2) CN101291954B (OSRAM)
AR (1) AR055137A1 (OSRAM)
AU (1) AU2006290433B2 (OSRAM)
BR (2) BR122020020335B1 (OSRAM)
CA (1) CA2619298C (OSRAM)
CL (2) CL2010000823A1 (OSRAM)
IL (1) IL189756A (OSRAM)
NO (2) NO345919B1 (OSRAM)
PH (1) PH12012502376B1 (OSRAM)
RU (2) RU2482132C2 (OSRAM)
SG (1) SG192479A1 (OSRAM)
TW (2) TWI615407B (OSRAM)
WO (1) WO2007031875A2 (OSRAM)
ZA (1) ZA200802500B (OSRAM)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
JP4653109B2 (ja) 2003-11-05 2011-03-16 ロシュ グリクアート アクチェンゲゼルシャフト 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体
NZ556286A (en) 2005-02-07 2010-11-26 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
CN101500597A (zh) 2005-06-17 2009-08-05 伊姆克罗尼系统公司 治疗转移性骨癌的受体拮抗剂
JP5373396B2 (ja) * 2005-08-26 2013-12-18 ロシュ グリクアート アクチェンゲゼルシャフト 改変された細胞シグナル活性有する改変抗原結合分子
KR101353706B1 (ko) 2006-02-03 2014-02-18 유니버시티 오브 워싱톤 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
CA2689941C (en) 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
ES2449070T3 (es) 2007-09-05 2014-03-18 F. Hoffmann-La Roche Ag Terapia de combinación con anticuerpos anti-CD20 de tipo I y tipo II
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP2011507897A (ja) * 2007-12-21 2011-03-10 ジェネンテック， インコーポレイテッド リツキシマブ抵抗性関節リウマチ患者の治療
RU2540013C2 (ru) * 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
JP5604311B2 (ja) * 2008-03-13 2014-10-08 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
CN102027017A (zh) * 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
TWI500624B (zh) * 2008-03-25 2015-09-21 Hoffmann La Roche 具有增進之抗體依賴型細胞毒性之第ii型抗－ｃｄ２０抗體之組合療法
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CA2722466A1 (en) * 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
EP2297208A4 (en) * 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
SG191639A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR20110031369A (ko) * 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
CA2738598C (en) * 2008-09-29 2017-11-21 Biotest Ag Composition for treating disease
US20100247484A1 (en) * 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
BRPI1012589A2 (pt) 2009-04-07 2016-03-22 Roche Glycart Ag anticorpos bi-específicos anti-erbb-3/anti-c-met
EP2417160A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-1/anti-c-met antibodies
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
US8815242B2 (en) * 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2012109451A (ru) * 2009-08-14 2013-09-27 Роше Гликарт Аг Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
RU2012112550A (ru) * 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
TW201119676A (en) * 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
MX2012007340A (es) 2009-12-22 2012-08-01 Roche Glycart Ag Anticuerpos anti/her3 y usos de los mismos.
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
CA2795544A1 (en) 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
KR20130045914A (ko) 2010-08-03 2013-05-06 에프. 호프만-라 로슈 아게 만성 림프구성 백혈병(cll) 생체지표
EP2601218A4 (en) 2010-08-03 2015-02-18 Abbvie Inc VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
AR082693A1 (es) * 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
BR112013004581A2 (pt) 2010-08-26 2017-06-27 Abbvie Inc imunoglobulinas de domínio variável dual e seus usos
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
KR20130088170A (ko) * 2010-12-16 2013-08-07 로슈 글리카트 아게 비푸코실화 ｃｄ20 항체와 ｍｄｍ2 저해제와의 조합 치료
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
HK1200850A1 (en) 2011-09-23 2015-08-14 罗氏格黎卡特股份公司 Bispecific anti-egfr/anti igf-1r antibodies
TW201945034A (zh) 2011-09-30 2019-12-01 日商中外製藥股份有限公司 包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
JP6309002B2 (ja) 2012-06-27 2018-04-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 標的に特異的に結合する少なくとも１つの結合実体を含む抗体Ｆｃ領域結合体を作製するための方法およびその使用
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
RU2636043C2 (ru) 2012-11-01 2017-11-17 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2953974B1 (en) 2013-02-05 2017-12-20 EngMab Sàrl Bispecific antibodies against cd3epsilon and bcma
MX365567B (es) 2013-03-13 2019-06-07 Genentech Inc Formulaciones de anticuerpo.
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
JP2017501157A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
TWI689520B (zh) 2014-05-30 2020-04-01 漢霖生技股份有限公司 抗表皮生長因子受體（ｅｇｆｒ）抗體
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
SI3262071T1 (sl) 2014-09-23 2020-07-31 F. Hoffmann-La Roche Ag Način uporabe imunokonjugatov proti CD79b
US20170313779A1 (en) * 2014-11-05 2017-11-02 The University Of Chicago Methods and compositions pertaining to human cerebral cavernous malformations
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CN107592812A (zh) * 2015-05-11 2018-01-16 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MX2017016651A (es) * 2015-06-24 2018-05-14 Hoffmann La Roche Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias.
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
EP3960765A1 (en) 2015-06-26 2022-03-02 Sanofi Biotechnology SAS Monoclonal anti-il-1racp antibodies
AU2016285596A1 (en) 2015-06-29 2018-01-18 Genentech, Inc. Type II anti-CD20 antibody for use in organ transplantation
HRP20200390T1 (hr) 2015-08-03 2020-06-12 Engmab Sàrl Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
EP4026848A1 (en) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
JP2019515874A (ja) * 2016-03-01 2019-06-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 改変された細胞死誘導を有するオビヌツズマブ変異体
JP2019516352A (ja) * 2016-04-01 2019-06-20 アムジエン・インコーポレーテツド Ｆｌｔ３に対するキメラ受容体及びその使用方法
US11649284B2 (en) 2016-04-18 2023-05-16 Baylor College Of Medicine Cancer gene therapy targeting CD47
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
TW201902512A (zh) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
US10148939B2 (en) 2016-07-19 2018-12-04 Gopro, Inc. Mapping of spherical image data into rectangular faces for transport and decoding across networks
IL266424B2 (en) 2016-11-02 2023-09-01 Engmab Sarl A bispecific antibody against bcma and cd3 and an immunological drug for combined treatment in multiple myeloma
IL267406B2 (en) 2016-12-20 2025-05-01 Hoffmann La Roche Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
WO2019020606A1 (en) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY
WO2019036433A2 (en) * 2017-08-16 2019-02-21 Bristol-Myers Squibb Company ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
CN119074915A (zh) 2018-03-13 2024-12-06 豪夫迈·罗氏有限公司 4-1bb激动剂与抗cd20抗体的治疗剂组合
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN112996801A (zh) * 2018-11-26 2021-06-18 北卡罗来纳州大学 用于捕获宿主细胞蛋白的肽配体
KR20210100668A (ko) 2018-12-06 2021-08-17 제넨테크, 인크. 항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
KR20220007136A (ko) 2019-05-14 2022-01-18 제넨테크, 인크. 소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
MX2021015540A (es) * 2019-06-19 2022-02-10 Hoffmann La Roche Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
US20220275065A1 (en) * 2019-07-31 2022-09-01 The Wistar Institute Of Anatomy And Biology Multivalent dna antibody constructs and use thereof
JP2022547577A (ja) 2019-09-12 2022-11-14 ジェネンテック， インコーポレイテッド ループス腎炎を治療する組成物及び方法
KR20220086618A (ko) 2019-10-18 2022-06-23 제넨테크, 인크. 미만성 거대 B-세포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
CN111411079B (zh) * 2020-03-27 2025-12-12 北京时合生物科技有限公司 细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用
CN115916822A (zh) 2020-04-24 2023-04-04 基因泰克公司 使用抗CD79b免疫缀合物的方法
EP4149547A4 (en) 2020-05-13 2024-08-14 Adagene AG Compositions and methods for treating cancer
IL304067A (en) 2021-01-06 2023-08-01 Hoffmann La Roche Combined treatment using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody
BR112023018621A2 (pt) 2021-03-15 2023-10-24 Hoffmann La Roche Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii
CN117396232A (zh) 2021-05-12 2024-01-12 基因泰克公司 使用抗cd79b免疫缀合物治疗弥漫性大b细胞淋巴瘤的方法
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2024062074A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use
TW202434286A (zh) 2022-11-08 2024-09-01 美商建南德克公司 治療兒童期發病的特發性腎病症候群之組成物及方法
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
ES2190087T3 (es) 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
PT2180007E (pt) * 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
ES2325642T3 (es) * 1998-05-20 2009-09-10 Kyowa Hakko Kirin Co Ltd Anticuerpos recombinantes genicos.
AU3041100A (en) * 1999-01-05 2000-07-24 Unilever Plc Binding of antibody fragments to solid supports
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
NZ523912A (en) 2000-07-31 2005-03-24 Biolex Inc Expression of biologically active polypeptides in duckweed
US20020128448A1 (en) 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
CA2442801A1 (en) * 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
NZ603111A (en) * 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
MXPA03012022A (es) * 2001-09-20 2005-07-01 Cornell Res Foundation Inc Metodos y composiciones para tratar o prevenir padecimientos de la piel, utilizando agentes de enlace especificos para el antigeno de membrana especifico de prostata.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR101001243B1 (ko) 2001-12-27 2010-12-17 글리코파이, 인크. 포유동물-유형 탄수화물 구조의 설계 방법
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003078614A2 (en) 2002-03-19 2003-09-25 Plant Research International B.V. Gntiii (udp-n-acethylglucosamine:beta-d mannoside beta (1,4)-n-acethylglucosaminy ltransferase iii) expression in plants
MXPA04009148A (es) * 2002-03-21 2005-02-28 Lilly Co Eli Anticuerpos humanos del ligando anti-hfas antagonisticos y sus fragmentos.
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20040132097A1 (en) 2002-06-19 2004-07-08 Bacus Sarah S. Method for predicting response to epidermal growth factor receptor-directed therapy
CA2495251C (en) * 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
WO2004024927A1 (en) 2002-09-12 2004-03-25 Greenovation Biotech Gmbh Protein production method
WO2004050850A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
AU2003294912B2 (en) 2002-12-20 2009-06-04 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP5425365B2 (ja) 2003-01-22 2014-02-26 グリカート バイオテクノロジー アクチェンゲゼルシャフト 増加したＦｃレセプター結合親和性およびエフェクター機能を有する抗体を作製するための融合構築物およびその使用
US7575893B2 (en) * 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
MXPA05009837A (es) * 2003-03-14 2005-12-05 Pharmacia Corp Anticuerpos para el receptor del factor de crecimiento tipo insulina-i, para el tratamiento de canceres.
CA2528434A1 (en) * 2003-06-05 2005-01-06 Genentech, Inc. Combination therapy for b cell disorders
CA2537055A1 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
JP4653109B2 (ja) * 2003-11-05 2011-03-16 ロシュ グリクアート アクチェンゲゼルシャフト 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体
JP4503617B2 (ja) * 2003-12-23 2010-07-14 ライナット ニューロサイエンス コーポレイション アゴニスト抗ｔｒｋＣ抗体および該抗体を用いる方法
AU2005214988A1 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US7572456B2 (en) * 2004-09-13 2009-08-11 Macrogenics, Inc. Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
TW200635607A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
US20090208500A1 (en) * 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
JP5373396B2 (ja) * 2005-08-26 2013-12-18 ロシュ グリクアート アクチェンゲゼルシャフト 改変された細胞シグナル活性有する改変抗原結合分子

Also Published As

Publication number Publication date
EP1931712B1 (en) 2018-12-05
NO345919B1 (no) 2021-10-18
EP2395024A2 (en) 2011-12-14
RU2012139197A (ru) 2014-03-20
CN101291954B (zh) 2013-03-27
HK1185357A1 (en) 2014-02-14
NO20081328L (no) 2008-05-23
BRPI0615397B1 (pt) 2023-10-03
AU2006290433B2 (en) 2012-06-07
RU2482132C2 (ru) 2013-05-20
EP2395023B1 (en) 2019-04-03
JP2009505650A (ja) 2009-02-12
JP2015078191A (ja) 2015-04-23
BRPI0615397A2 (pt) 2011-05-17
EP2395023A3 (en) 2012-02-01
ZA200802500B (en) 2023-04-26
EP2395024A3 (en) 2012-02-22
CL2010000822A1 (es) 2011-01-07
PH12012502376A1 (en) 2016-01-11
JP6081974B2 (ja) 2017-02-15
BR122020020335B1 (pt) 2023-10-03
WO2007031875A2 (en) 2007-03-22
AU2006290433A1 (en) 2007-03-22
JP5373396B2 (ja) 2013-12-18
CN103204935B (zh) 2014-12-10
KR101460932B1 (ko) 2014-11-12
NO20210557A1 (no) 2008-05-23
RU2008111068A (ru) 2009-10-10
CA2619298C (en) 2017-07-04
KR20130119988A (ko) 2013-11-01
EP2395023A2 (en) 2011-12-14
PH12012502376B1 (en) 2018-11-14
KR20080040036A (ko) 2008-05-07
US20150344584A1 (en) 2015-12-03
TW201527324A (zh) 2015-07-16
JP2013116120A (ja) 2013-06-13
CN103204935A (zh) 2013-07-17
SG192479A1 (en) 2013-08-30
CN101291954A (zh) 2008-10-22
AR055137A1 (es) 2007-08-08
TWI615407B (zh) 2018-02-21
KR101379568B1 (ko) 2014-04-08
EP2395024B1 (en) 2018-12-19
TWI478940B (zh) 2015-04-01
CA2619298A1 (en) 2007-03-22
TW200804423A (en) 2008-01-16
IL189756A (en) 2017-08-31
RU2547931C2 (ru) 2015-04-10
EP1931712A2 (en) 2008-06-18
WO2007031875A3 (en) 2008-02-14
US20070071745A1 (en) 2007-03-29
JP5912090B2 (ja) 2016-04-27

Similar Documents

Publication Publication Date Title
CL2010000823A1 (es) Anticuerpo anti-cd-20 con actividad apoptotica; polinucleotido, vector y celula huesped que expresa el anticuerpo; composicion farmaceutica que lo comprende; usos en la preparacion de un medicamento para tratar cancer o una enfermedad autoinmune; metodo para producir dicho anticuerpo (div. sol. n°2246-06).
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
AR120563A1 (es) Receptores de antígeno quimérico cd19 y cd22 y sus usos
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
AR115389A1 (es) Anticuerpo antagonista de cd73
AR106232A1 (es) Anticuerpos anti-pd1 (proteína muerte programada 1) y métodos de uso
CL2018003807A1 (es) Anticuerpo humanizado aislado que une al cd134 humano; molécula de ácido nucleico aislada; vector que comprende a la misma célula anfitriona que comprende al mismo; uso del anticuerpo para potenciar una respuesta inmune; uso del anticuerpo para el tratamiento del cáncer, una composición farmacéutica que comprende el anticuerpo. (divisional solicitud 201502793)
MX374810B (es) Anticuerpos 4-1bb anti-humano y usos de los mismos
AR073425A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina
PE20161389A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
EA202091566A1 (ru) Содержащая нуклеиновую кислоту липидная наночастица и ее применение
AR063829A1 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
AR071510A1 (es) Anticuerpos anti- factor d humanizados y sus usos
PE20140247A1 (es) Anticuerpos anti-cd38
PE20250415A1 (es) Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos
AR086511A2 (es) Agentes de union especifica al factor de crecimiento de hepatocitos
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
PE20190108A1 (es) Moleculas de anticuerpo para el tratamiento del cancer
PE20190976A1 (es) Anticuerpos de union a cd3
PE20191487A1 (es) Anticuerpos anti-gitr y metodos de uso de los mismos
EA201790366A1 (ru) Сахариды и сахаридные композиции и смеси
AR095432A1 (es) Proteínas de unión a antígeno
MX2017011329A (es) Productos terapeuticos de anticuerpos que se enlazan a cd47.